Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

ProQR Therapeutics « Terug naar discussie overzicht

ProQR Therapeutics 2019

2.656 Posts, Pagina: « 1 2 3 4 5 6 ... 66 67 68 69 70 71 72 73 74 75 76 ... 129 130 131 132 133 » | Laatste

Omlaag ↓

[verwijderd] 18 juli 2019 20:49

Omschrijf het eens in het Nederlands?

nb 19 juli 2019 06:44

Vertaling : het had zomaar proqr kunnen zijn

nb 19 juli 2019 06:45

Of arwh

Sentiment 19 juli 2019 18:23

Zou PRQR nu bijna op een kantelpunt staan?
Er zouden toch best snel weer koersen van rond de 10$ kunnen komen?

4finance 19 juli 2019 19:25

Nog wat Proqr gekocht. Heeft iemand een mening over Arbutus Biopharma Corporation (ABUS) ?

Tom3 20 juli 2019 10:53

Ik had ABUS bijna voor $ 2,40 gekocht. Blij dat mij beperkt heb tot Arrowhead. De delivery bij RNAi blijkt cruciaal. ABUS moet nog aantonen dat haar Galnac methode gaat werken. Daarnaast is hun pijplijn erg mager. Als je er in gaat gok je op een bedrijfsovername. Ik beperk me liever tot clubs met bewezen technologie.

[verwijderd] 20 juli 2019 12:22

ABUS technology works as it is what ALNY uses in its approved drug Tom.
in addition its pipeline is not thin. it has created at least 2 spin outs that leverage its technology .. Genvant i believe is one of them and it will have a growing pipeline.. ABUS is set to receive royalties once the products go to market

ABUS however restricted itself internally to HBV which is a tough nut to crack. the potential is huge however. In its trial their drug sort of works. but there is more to work on to make it happen.
ALso ABUS valuation is under cash.

Abus is a turnaround story with a new CEO and a technology that works in the RNAi space. I am not invested in it but if compared to ARWR .. valuations, technology, potential , risks and all.. I personally would had preferred ABUS over ARWR.
and some of the price targets show that ARWR could go up 50% where ABUS could go up 500%

but better than ABUS is I think RGLS which will come out w its own HBV candidate this yr.

[verwijderd] 20 juli 2019 12:41

but back to Proqr ... I hope that phase1/2 results will provide it conditional approval in Europe at least. I looked if thats possible and found www.spglobal.com/marketintelligence/e... that based on the news, there is conditional approvals given... and phase 3 have to collaborate.

If the phase1/2 results in September are as good or better than Proqr has reported to date... then........ and dont want to get too excited and pump here but..

have a good weekend y all

nb 20 juli 2019 16:10

thnx Joel, for your input. The market is not awake yet for what regulus concerns. But i have put a 1000 euros in it, just to wait for further details. If it explodes, hurray, if not, a pity but not too much lost

nb 20 juli 2019 16:11

and a nice weekend y all

[verwijderd] 20 juli 2019 20:29

RGLS is getting heavily accumulated, and in the coming months its supposed to have the following catalysts
1) get 20mill from Sanofi for this continuing the licensed program. I know for sure it will happen... only this catalyst could double the valuation.

2) for RGLS to restart its kidney program which was on hold. the indication is bigger than cystic fibrosis!

3) license out the various programs
NASH
GBM Cancer
HCV

4) become clinical with its HBV program.

at current valuation compared to the above you can appreciate that it can explode to say the least... but I agree it also has risks and thus it needs to be held in the appropriate QTYs...

Hunter300 20 juli 2019 20:45

What about neurotrope? About 80 M mcap and waiting for read out of confirmatory phase 2b. A lot of bashers on fora but I have not seen a valid argument contra. The are aiming for a drug against moderate to severe Alzheimer’s disease.
Potentially the biggest commercial opportunity.

[verwijderd] 21 juli 2019 10:03

neurotrope looks more like a scam than an viable company. imho.
the company has like 1 in 1000000000 chance to ever come with anything. and its valuation is many times over compared to other bios if compared value/cash
if alzheimer is something you can about the companies to look into is..
PROQR ... I can go in length why.
some others to mention that have some type of a chance..
RGLS.. I can go into why
VCNX ... small but some chance.
XENE.. the chance became bigger for it based on new research.

Hunter300 21 juli 2019 12:24

I agree investment in AD is extremely high risk. Everything else to date has failed, including huge projects from the main pharma companies. Reading all the ‘articles’ on the internet (e.g. seeking alpha) didn’t encourage me to buy shares either. However, I was triggered by the degree some people persevere in bashing this stock (shorters using the failure percentage of 100% in this complex indication?). In addition, the seemingly high level of science in these’ articles’ made me look into it a bit further and what I found is that 99% of all arguments used against this specific investment proposition is not accurate/valid. Most potential investors do not have sufficient scientific background to not be impressed by these hit articles.

What I found is that the mechanism completely differs from what has been tested before, this tells me the history of 100% failure rate does not necessarily apply to this project. Moreover, preclinical and clinical data so far do show the principle works. The last phase 2 study did not reach statistical significance because many patients used background medication that interfered with the mechanism currently tested. The confirmatory study excluded the use of this concomitant drug. In addition, I found an article in a peer reviewed journal where I find the science behind the theory/principle is supported. (https://res.mdpi.com/ijms/ijms-20-03544/article_deploy/ijms-20-03544.pdf?filename=).

Can you explain why you feel this company is scam (apart from the short-articles). I agree cash is low but what if the trial outcome is positive?

[verwijderd] 21 juli 2019 15:57

I didnt read even the short articles to figure out the company is MOST LIKELY a scam. I didnt know the company before, learned it from your question for the first time and looked it up and did a brief investigation.
the company is trading on the OTCBB market which is not regulated very well therefore the company can post whatever info and pump itself up without being supervised.
more so than reading the short thesis or whatever, I would be worried about who is pushing up this stock and this company..
look any drug tested has a chance to succeed .. even 1 in 10000000 is a chance.
however just by briefly looking into the company I for myself think the chance is that 1 in 1000000 in not more .. but there is that chance and each one should think how to invest.
Between that company and a list of others including PRQR which has the technology to one day if focused on it .. truly wipe out Alzheimers.. to invest in the others.. I think is a better choice.

Hunter300 21 juli 2019 20:25

Fair enough. I did not know about the limited regulation. I have seen indeed some comments that very limited data was shared about the subpopulation for which they found a decent response. I guessed they should have at least provided that information to the FDA/IRB in order to get approval for this confirmatory study. I wonder whether investigators would enroll subjects in this study when their experience in the previous study has been negative. Anyway, I agree the risk of failing is probably close to 100%. I’ll consider this investment as lost money.

@Tom3: heb jij hier een mening over?

[verwijderd] 22 juli 2019 05:42

look I looked again on the company and some of the people involved in it where prosecuted in the past on scams biotech investing.

with this said the element used in their drug a marine component is thought to help with Alzheimer .. the question is how much or how good they synthesized the drug and all... who knows? maybe they will succeed ... hard to say .. so maybe you will make it afterall .. its a gamble here probably would had been wise to buy it close to cash.. so about 1/3 or so current valuation to be safer .

Tom3 22 juli 2019 14:28

quote:
Hunter300 schreef op 21 juli 2019 20:25:
Fair enough. I did not know about the limited regulation. I have seen indeed some comments that very limited data was shared about the subpopulation for which they found a decent response. I guessed they should have at least provided that information to the FDA/IRB in order to get approval for this confirmatory study. I wonder whether investigators would enroll subjects in this study when their experience in the previous study has been negative. Anyway, I agree the risk of failing is probably close to 100%. I’ll consider this investment as lost money.

@Tom3: heb jij hier een mening over?

Afblijven:
blogs.sciencemag.org/pipeline/archive...

Tom3 22 juli 2019 14:31

quote:
joel12 schreef op 20 juli 2019 20:29:
RGLS is getting heavily accumulated, and in the coming months its supposed to have the following catalysts
1) get 20mill from Sanofi for this continuing the licensed program. I know for sure it will happen... only this catalyst could double the valuation.

2) for RGLS to restart its kidney program which was on hold. the indication is bigger than cystic fibrosis!

3) license out the various programs
NASH
GBM Cancer
HCV

4) become clinical with its HBV program.

at current valuation compared to the above you can appreciate that it can explode to say the least... but I agree it also has risks and thus it needs to be held in the appropriate QTYs...

The stock imploded from $ 200+ in 2015 to $ 1+ now. I will check.

4finance 22 juli 2019 18:16

quote:
Tom3 schreef op 22 juli 2019 14:31:
[...]

The stock imploded from $ 200+ in 2015 to $ 1+ now. I will check.

Vandaag mijn positie Proqr verder uitgebreid. Lijkt nu te bodemen. De tip van RGLS gelezen. Heb er een paar K gekocht. Je zou zeggen daar moet toch wat muziek in zitten ;-) Van $239 naar $1,00. Je verzint het niet....

2.656 Posts, Pagina: « 1 2 3 4 5 6 ... 66 67 68 69 70 71 72 73 74 75 76 ... 129 130 131 132 133 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	24 apr 2024 22:00
Koers	2,010
Verschil	-0,010 (-0,50%)
Hoog	2,040
Laag	1,970
Volume	36.411
Volume gemiddeld	204.827
Volume gisteren	249.624

ProQR Therapeutics NV nieuws

Meer ››